{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:02Z","timestamp":1793932502228,"version":"4.8.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neurological disorders pose a rapidly growing global health burden, significantly affecting cognitive and motor functions with profound societal repercussions. This comprehensive review probe into the genetic foundations of various neurological conditions while exploring innovative RNA-based therapeutics particularly gene therapies as cutting edge treatment strategies. Through an in-depth analysis of existing literature, the study examines the genetic landscape, disease mechanisms, and gene-based intervention possibilities across a range of neurological disorders, including Cerebellar Ataxias, Autosomal Recessive Ataxia, Mitochondrial Cerebellar Ataxia, Multiple System Atrophy (MSA), Idiopathic Late-Onset Cerebellar Ataxia, Hereditary Spastic Paraplegias, Alzheimer\u2019s Disease, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementias, Inherited Prion Diseases, and Huntington\u2019s Disease. It uncovers the intricate network of genetic mutations driving these disorders, shedding light on their mechanisms and uncovering promising therapeutic targets. The review also highlights the remarkable potential of RNA-based therapeutics, with gene therapies standing at the forefront of precision treatment approaches. By offering an up-to-date understanding of the genetic intricacies and emerging therapeutic possibilities in neurological disorders, this study significantly contributes to the advancement of precision medicine in neurology. It also paves the way for future research and clinical applications aimed at improving patient care and outcomes.<\/jats:p>","DOI":"10.3389\/fneur.2025.1422707","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:07:36Z","timestamp":1744340856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Decoding the genetic blueprints of neurological disorders: disease mechanisms and breakthrough gene therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Umar","family":"Saeed","sequence":"first","affiliation":[{"name":"Operational Research Center in Healthcare, Near East University","place":["Nicosia, T\u00fcrkiye"]},{"name":"Foundation University School of Health Sciences (FUSH), Foundation University Islamabad","place":["Islamabad, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Zahid","family":"Piracha","sequence":"additional","affiliation":[{"name":"International Center of Medical Sciences Research (ICMSR)","place":["Islamabad, Pakistan"]},{"name":"International Center of Medical Sciences Research (ICMSR)","place":["Austin, TX, United States"]},{"name":"International Center of Medical Sciences Research (ICMSR)","place":["Essex, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nouman","family":"Tariq","sequence":"additional","affiliation":[{"name":"Akhtar Saeed Medical & Dental College","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shayan","family":"Gilani","sequence":"additional","affiliation":[{"name":"Akhtar Saeed Medical & Dental College","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rauf","sequence":"additional","affiliation":[{"name":"University College of Medicine and Dentistry","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Razaq","sequence":"additional","affiliation":[{"name":"Akhtar Saeed Medical & Dental College","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kaleem","family":"Iftikhar","sequence":"additional","affiliation":[{"name":"Punjab Institute of Neurosciences","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Maqsood","sequence":"additional","affiliation":[{"name":"Akhtar Saeed Medical & Dental College","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"952161","DOI":"10.3389\/fpubh.2022.952161","article-title":"Global, regional, and national burden and attributable risk factors of neurological disorders: the global burden of disease study 1990-2019","volume":"10","author":"Ding","year":"2022","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1212\/WNL.0000000000000610","article-title":"The global burden of neurologic diseases","volume":"83","author":"Chin","year":"2014","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051709","article-title":"Advances in neurodegenerative diseases","volume":"12","author":"Van Schependom","year":"2023","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/15476286.2021.2021650","article-title":"RNA-based therapeutics for neurological diseases","volume":"19","author":"Anthony","year":"2022","journal-title":"RNA Biol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3390\/ijms22105057","article-title":"Factors associated with mutations: their matching rates to cardiovascular and neurological diseases","volume":"22","author":"Lucas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1212\/CON.0000000000000753","article-title":"Ataxia","volume":"25","author":"Kuo","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2014","journal-title":"Acta Neuropathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias","volume":"16","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2014.05.032","article-title":"Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance","volume":"85","author":"Jiang","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-1-47","article-title":"Autosomal recessive cerebellar ataxias","volume":"1","author":"Palau","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich's ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook","year":"2017","journal-title":"Br Med Bull"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/TRD-160005","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl Sci Rare Dis"},{"key":"ref17","first-page":"1993","volume-title":"FMR1 disorders","author":"Hunter","year":"1998"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/neurolint14020028","article-title":"Mitochondrial ataxias: molecular classification and clinical heterogeneity","volume":"14","author":"Lopriore","year":"2022","journal-title":"Neurol Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Taylor","year":"2019","journal-title":"Mol Neurodegener"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3389\/fcell.2020.600079","article-title":"The dimensions of primary mitochondrial disorders","volume":"8","author":"Schlieben","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.mito.2007.03.008","article-title":"The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease","volume":"7","author":"Haas","year":"2007","journal-title":"Mitochondrion"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1093\/hmg\/ddw257","article-title":"The COQ2 genotype predicts the severity of coenzyme Q10 deficiency","volume":"25","author":"Hirano","year":"2016","journal-title":"Hum Mol Genet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1028762","DOI":"10.3389\/fnins.2022.1028762","article-title":"Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with an MT-TL1 m.3243A>G point mutation: neuroradiological features and their implications for underlying pathogenesis","volume":"16","author":"Zheng","year":"2023","journal-title":"Front Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/mds.25847","article-title":"Multiple system atrophy of the cerebellar type: clinical state of the art","volume":"29","author":"Lin","year":"2014","journal-title":"Mov Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","article-title":"Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia","volume":"51","author":"Cortese","year":"2019","journal-title":"Nat Genet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/practneurol-2018-002096","article-title":"Diagnosis and management of progressive ataxia in adults","volume":"19","author":"de Silva","year":"2019","journal-title":"Pract Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-022-00579-z","article-title":"Multiple system atrophy: \u03b1-synuclein strains at the neuron-oligodendrocyte crossroad","volume":"17","author":"Reddy","year":"2022","journal-title":"Mol Neurodegener"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0888-7543(95)80237-G","article-title":"The human NACP\/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis","volume":"26","author":"Chen","year":"1995","journal-title":"Genomics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-019-0769-4","article-title":"Cross-examining candidate genes implicated in multiple system atrophy","volume":"7","author":"Katzeff","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/mds.21343","article-title":"G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy","volume":"22","author":"Ozelius","year":"2007","journal-title":"Mov Disord"},{"key":"ref31","first-page":"4256","article-title":"The COQ2 genotype predicts the severity of coenzyme Q10 deficiency","volume-title":"Hum Mol Genet","author":"Desbats","year":"2016"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jnc.13600","article-title":"Tau physiology and pathomechanisms in frontotemporal lobar degeneration","volume":"138","author":"Bodea","year":"2016","journal-title":"J Neurochem"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-023-03905-1","article-title":"The genetic basis of multiple system atrophy","volume":"21","author":"Tseng","year":"2023","journal-title":"J Transl Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00401-013-1115-8","article-title":"Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms","volume":"126","author":"Fink","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10072-020-04981-7","article-title":"Hereditary spastic paraplegia","volume":"42","author":"Murala","year":"2021","journal-title":"Neurol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12883-022-02595-4","article-title":"An integrated modelling methodology for estimating global incidence and prevalence of hereditary spastic paraplegia subtypes SPG4, SPG7, SPG11, and SPG15","volume":"22","author":"Vander Stichele","year":"2022","journal-title":"BMC Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"660714","DOI":"10.3389\/fnins.2021.660714","article-title":"Hereditary spastic paraplegia and future therapeutic directions: beneficial effects of small compounds acting on cellular stress","volume":"15","author":"Gumeni","year":"2021","journal-title":"Front Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/brainsci8080142","article-title":"Patient-derived stem cell models in SPAST HSP: disease modelling and drug discovery","volume":"8","author":"Wali","year":"2018","journal-title":"Brain Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e00660","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson's disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol Cell Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(05)17830-1","article-title":"A common LRRK2 mutation in idiopathic Parkinson's disease","volume":"365","author":"Gilks","year":"2005","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/jmg.2008.063917","article-title":"Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control","volume":"46","author":"Brooks","year":"2009","journal-title":"J Med Genet"},{"key":"ref43","first-page":"1887","article-title":"Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway","volume":"10","author":"Zhou","year":"2018","journal-title":"Am J Transl Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JPD-201981","article-title":"Mitochondria and Parkinson's disease: clinical, molecular, and translational aspects","volume":"11","author":"Borsche","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","article-title":"APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoisel\u00e9e","year":"2017","journal-title":"PLoS Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer's disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","article-title":"Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE","volume":"83","author":"Bertram","year":"2008","journal-title":"Am J Hum Genet"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00415-011-6145-3","article-title":"Progress in Alzheimer\u2019s disease","volume":"259","author":"Galimberti","year":"2012","journal-title":"J Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s12951-023-02250-1","article-title":"Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective","volume":"21","author":"Nayab","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol Cancer"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","article-title":"Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease","volume":"131","author":"Kalaria","year":"2016","journal-title":"Acta Neuropathol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/jpm11060474","article-title":"Genetic counselling improves the molecular characterisation of dementing disorders","volume":"11","author":"Zampatti","year":"2021","journal-title":"J Pers Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"751044","DOI":"10.3389\/fnmol.2022.751044","article-title":"Identification of molecular signatures and candidate drugs in vascular dementia by bioinformatics analyses","volume":"15","author":"Shu","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.2147\/DDDT.S90580","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/HMER.S230613","article-title":"Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data","volume":"12","author":"Diaz Soto","year":"2020","journal-title":"Hepat Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.4049\/jimmunol.0903487","article-title":"The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity","volume":"184","author":"Shi","year":"2010","journal-title":"J Immunol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/btt.s12160292","article-title":"Efalizumab in the treatment of psoriasis","volume":"1","author":"Boehncke","year":"2007","journal-title":"Biologics"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11910-018-0874-y","article-title":"The genetics of dementia with Lewy bodies: current understanding and future directions","volume":"18","author":"Orme","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1073\/pnas.91.11.4611","article-title":"Inherited prion diseases","volume":"91","author":"Outeiro","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","article-title":"Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture","volume":"53","author":"Chia","year":"2021","journal-title":"Nat Genet"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/0972-2327.74249","article-title":"Frontotemporal dementias: recent advances and current controversies","volume":"13","author":"Leyton","year":"2010","journal-title":"Ann Indian Acad Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2174\/1567205014666170426105713","article-title":"Genetic features of MAPT, GRN, C9orf72 and CHCHD10 gene mutations in Chinese patients with frontotemporal dementia","volume":"14","author":"Che","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-008-0397-8","article-title":"Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions","volume":"116","author":"Josephs","year":"2008","journal-title":"Acta Neuropathol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","article-title":"C9orf72-mediated ALS and FTD: multiple pathways to disease","volume":"14","author":"Balendra","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.abq7860","article-title":"Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration","volume":"378","author":"Shao","year":"2022","journal-title":"Science"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"108200","DOI":"10.1016\/j.exer.2020.108200","article-title":"Prions and prion diseases: insights from the eye","volume":"199","author":"Singh","year":"2020","journal-title":"Exp Eye Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"a024364","DOI":"10.1101\/cshperspect.a024364","article-title":"Sporadic and infectious human prion diseases","volume":"7","author":"Will","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00401-010-0713-y","article-title":"Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy","volume":"121","author":"Kovacs","year":"2011","journal-title":"Acta Neuropathol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.2147\/NDT.S165445","article-title":"Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases","volume":"14","author":"Bagyinszky","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","article-title":"Neuropsychiatry of Huntington's disease","volume":"9","author":"Rosenblatt","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"ref73","first-page":"16","article-title":"Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am J Hum Genet"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref75","first-page":"17","article-title":"Tetrabenazine","volume-title":"Nat Rev Drug Discov","author":"Hayden","year":"2009"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/sj.npp.1301377","article-title":"Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models","volume":"32","author":"Choi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cmet.2016.09.004","article-title":"NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair","volume":"24","author":"Fang","year":"2016","journal-title":"Cell Metab"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/joim.13815","article-title":"Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs","volume":"296","author":"Paucar","year":"2024","journal-title":"J Intern Med"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1590\/1678-4685-gmb-2018-0159","article-title":"Lysosomal diseases: overview on current diagnosis and treatment","volume":"42","author":"Poswar","year":"2019","journal-title":"Genet Mol Biol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e0003","DOI":"10.5041\/RMMJ.10003","article-title":"Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson's disease with neuroprotective potential","volume":"1","author":"Finberg","year":"2010","journal-title":"Rambam Maimonides Med J"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/alz.12334","article-title":"Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD-MOD)","volume":"17","author":"Galvin","year":"2021","journal-title":"Alzheimers Dement"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1422707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:50:38Z","timestamp":1792414238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1422707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":81,"alternative-id":["10.3389\/fneur.2025.1422707"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1422707","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1422707"}}